2/8/2007 11:56:45 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that it has acquired the intellectual property assets of its former competitor Infigen, Inc. relating to somatic cell nuclear transfer (SCNT), parthenogenesis, and other related technologies. A total of 26 issued patents and numerous pending patent applications were acquired for a combination of cash and shares of common stock. The acquisition provides ACTC with exclusive ownership rights to critical technologies in regenerative medicine and the merger of assets is expected to strengthen ACTC’s intellectual property position in the drive towards commercialization of embryonic stem cell and SCNT technology.
comments powered by